Satellos Bioscience Inc Dossier - Source-backed chat

Satellos Bioscience Inc

MSCLToronto Stock Exchange

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.10

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $8.50Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $180.3M

Enterprise Value $170.5M

Shares Outstanding 21.2M diluted

Moat Rating None

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Satellos Bioscience Inc. is a clinical-stage biotechnology company developing SAT-3247, a first-of-its-kind, orally administered small molecule therapy designed to restore the body's natural muscle repair and regeneration process. By targeting AAK1 to correct muscle stem cell polarity, SAT-3247 operates in a dystrophin-independent manner, offering potential as a standalone or combination therapy for Duchenne muscular dystrophy (DMD) and other degenerative muscle diseases like FSHD. Backed by a strong cash runway extending through 2027 and positive interim Phase 2 data, Satellos represents a compelling high-upside opportunity in the regenerative medicine space.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$20.00

Mean target$27.67

High · most bullish analyst$40.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$11.0020%

Clinical trials face unexpected safety concerns or fail to show statistically significant improvements in muscle quality and function over placebo. Enrollment delays in BASECAMP or TRAILHEAD extend the timeline, accelerating cash burn and forcing highly dilutive equity financing before meaningful clinical proof-of-concept is established.

Base CaseCentral scenario

$18.0050%

Satellos successfully completes enrollment for the BASECAMP trial in Q3 2026 and continues to report positive safety and functional efficacy data from the TRAILHEAD trial. The cash runway remains sufficient through 2027 to reach key clinical readouts, supporting steady valuation appreciation as the pipeline matures and the company prepares for registrational trials.

Bull CaseUpside scenario

$23.0030%

SAT-3247 demonstrates exceptional disease-modifying efficacy in both the pediatric BASECAMP and adult TRAILHEAD Phase 2 trials, showing superior muscle regeneration and strength gains compared to natural history. The drug's dystrophin-independent mechanism allows it to be positioned as a universal combination therapy alongside existing gene therapies (e.g., Sarepta's Elevidys), leading to rapid market adoption, potential out-licensing deals, and expansion into FSHD.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Novel, first-in-class mechanism of action targeting AAK1 to restore muscle stem cell polarity and regeneration.
Dystrophin-independent approach allows broad applicability across all DMD mutations and potential combination use with gene therapies.
Robust cash position of $69.9M (as of March 31, 2026) providing a clear runway through 2027.
Promising preclinical data supporting pipeline expansion into facioscapulohumeral muscular dystrophy (FSHD).

Key Investment Risks

High-stakes binary clinical trial risk associated with ongoing Phase 2 BASECAMP and TRAILHEAD studies.
Intense competition in the DMD therapeutic landscape from established gene and RNA therapies.
Pre-revenue status with long-term dependence on capital markets or strategic partnerships for funding.

Thesis Invalidation Triggers

Failure of SAT-3247 to meet primary safety or tolerability endpoints in Phase 2 trials.
Inability to demonstrate superior functional efficacy (e.g., handgrip or dynamometry strength) compared to placebo or natural history.
Significant delays in BASECAMP enrollment beyond Q3 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.